PAPPA and gestational diabetes: This study investigated the potential of first-trimester biomarkers, PAPP-A MoM and free β-hCG MoM levels, which are routinely used for aneuploidy screening between 11 and 14 weeks’ gestation, as possible screening markers for GDM, including insulin-dependent GDM.